Glaxo calms fears over loss of Zantac patent
Friday 07 March 1997
Sir Richard Sykes, the chief executive who will take over the chairmanship in May, warned that sales of Zantac, just under a quarter of the group total last year, could plunge by as much as 80 per cent after the patent expires in July.
But in a clear message to analysts who have suggested earnings at the group could go into reverse, he said he expected turnover growth to be back up in double-digit percentages by 1999, while earnings would be "at least maintained" over the next two years.
Products introduced since 1990 hit sales of pounds 2bn last year, overtaking Zantac for the first time, Sir Richard said. "Sales of new products give us confidence as we go forward into 1997 and 1998, which will be tough years. Even under the worst-case scenario for that business, we can grow the business in low single-digit numbers and once we get through 1998, we have confidence we can grow in double digits."
The outcome of Glaxo's appeal against a US court ruling allowing rival drugs group Novopharm to sell a generic form of Zantac is expected shortly. Sir Richard said Glaxo would announce strategies for dealing with the competition, which would only hit around 10 per cent of the group's sales, by July.
The shares, which initially dipped 28.5p yesterday, ended 14p ahead at pounds 10.49.
One analyst said for the first time the company had looked over to the other side of the Zantac chasm: "Today could mark an important turning point at Glaxo in that the stock market may now start to focus on life beyond Zantac."
Steve Plag at Barclays de Zoete Wedd, the stockbrokers, said sales growth excluding Zantac was 14 per cent last year, led by products introduced since 1990. Between now and the end of the century, the company would launch another 20 drugs, he said. "We all know 1997 is going to be a very, very tough year, but by 1999, this company is going to look very, very different."
Sir Richard's comments came as Glaxo Wellcome announced pre-tax profits of pounds 2.96bn for last year, 18 per cent ahead of the figure for the 12 months to December 1995, excluding the costs of integrating Wellcome. The results covered the first full year since the pounds 9bn acquisition of the drugs group. John Coombe, Glaxo finance director, said the integration was "bang on target", delivering pounds 150m of savings last year. Most of the 7,500 planned cut in the combined groups' workforce had been achieved, and the focus was moving from research and development activities to manufacturing operations.
Glaxo said sales of anti-HIV products more than doubled to pounds 500m last year.
Investment column, page 23
- 1 I was a Woman Against Feminism too
- 2 Is Gideon Levy the most hated man in Israel or just the most heroic?
- 3 Chief Ebola doctor in Sierra Leone has contracted the deadly disease himself
- 4 Students offered grants if they tweet pro-Israeli propaganda
- 5 Israel has discovered that it's no longer so easy to get away with murder in the age of social media
Lana Del Rey: 'I have slept with a lot of guys in the industry'
Vladimir Putin employs a full-time food taster to ensure his meals aren't poisoned
Chief Ebola doctor in Sierra Leone has contracted the deadly disease himself
Students offered grants if they tweet pro-Israeli propaganda
Israel-Gaza conflict: Israel may have committed war crimes, says UN human rights chief
Malaysia Airlines MH17 crash: Vladimir Putin is given 'one last chance' to end hostilities in Ukraine
The 'scroungers’ fight back: The welfare claimants battling to alter stereotypes
The truth about conspiracy theories is that some require considering
Malaysia Airlines MH17 crash: Ukrainian military jet was flying close to passenger plane before it was shot down, says Russian officer
Malaysia Airlines MH17 crash: Massive rise in sale of British arms to Russia
Malaysia Airlines MH17 crash: victims’ bodies bundled in black bags and loaded onto trains
iJobs Money & Business
£350 - £400 per day: Orgtel: PMO Analyst - Banking - London - £350 -£400 per d...
£300 - £350 per day + competitive: Orgtel: Cost Reporting Manager - MI Packs -...
£35000 - £40000 Per Annum plus 23 days holiday and pension scheme: Clearwater ...
£475 - £525 per day: Orgtel: Test Lead, London, Investment Banking, Technical ...